RxSight Q2 revenue $33.7M, product sales down 19% YoY; withdraws 2026 guidance

RxSight, Inc.

Product sales $27.2M (-19% YoY); LAL units 24,917; LDD units 12.
Net loss $(12.1)M ($(0.29)/share); adjusted net loss $(4.6)M ($(0.11)/share).
New CEO Aziz Mottiwala appointed; Alcon collaboration with up to $200M in payments.
Next-gen Light Adjustable Technology platform announced; 2026 guidance withdrawn.
Cash and investments $208.8M as of June 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.